Research article: Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma

PPAR Research

Volumn , Issue , 2010, Pages

  Meyer, Stefanie ^a   Vogt, Thomas ^a   Landthaler, Michael ^a   Berand, Anna ^a   Reichle, Albrecht ^a   Bataille, Frauke ^a   Marx, Andreas H ^b   Menz, Anne ^b   Hartmann, Arndt ^c   Kunz Schughart, Leoni A ^d   Wild, Peter J ^e  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROFECOXIB; TROFOSFAMIDE; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NEVUS; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SKIN CANCER; TISSUE MICROARRAY;

EID: 84868307362     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2010/848645     Document Type: Article

References (32)

1. T. Hla and K. Neilson, "Human cyclooxygenase-2 cDNA," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 16, pp. 7384-7388, 1992.
2. A. J. Dannenberg, N. K. Altorki, J. O. Boyle, D. T. Lin, and K. Subbaramaiah, "Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract," Annals of the New York Academy of Sciences, vol. 952, pp. 109-115, 2001. (Pubitemid 34060013)
3. M. J. Thun, S. J. Henley, and T. Gansler, "Inflammation and cancer: an epidemiological perspective," Novartis Foundation Symposium, vol. 256, pp. 6-21, 2004.
4. C. Bucher, P. Jordan, V. Nickeleit, J. Torhorst, and M. J. Mihatsch, "Relative risk of malignant tumors in analgesic abusers. Effects of long-term intake of aspirin," Clinical Nephrology, vol. 51, no. 2, pp. 67-72, 1999. (Pubitemid 29074189)
5. M. Oshima, N. Murai, S. Kargman, et al., "Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor," Cancer Research, vol. 61, no. 4, pp. 1733-1740, 2001. (Pubitemid 34292612)
6. C. Denkert, M. Köbel, S. Berger, et al., "Expression of cyclooxygenase 2 in human malignant melanoma," Cancer Research, vol. 61, no. 1, pp. 303-308, 2001. (Pubitemid 32095731)
7. C. Lee, J. A. Ramirez, J. Guitart, and L. K. Diaz, "Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression," Journal of Cutaneous Pathology, vol. 35, no. 11, pp. 989-994, 2008.
8. S. Y. Buckman, A. Gresham, P. Hale, et al., "COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer," Carcinogenesis, vol. 19, no. 5, pp. 723-729, 1998. (Pubitemid 28376760)
9. T. Nijsten, E. Geluyckens, C. Colpaert, and J. Lambert, "Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors," Journal of Cutaneous Pathology, vol. 32, no. 5, pp. 340-347, 2005. (Pubitemid 40547792)
10. H. P. Koeffler, "Peroxisome proliferator-activated receptor gamma and cancers," Clinical Cancer Research, vol. 9, no. 1, pp. 1-9, 2003. (Pubitemid 36109710)
11. E. Mueller, M. Smith, P. Sarraf, et al., "Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 10990-10995, 2000.
12. V. Subbarayan, A. L. Sabichi, J. Kim, et al., "Differential peroxisome proliferator-activated receptor-γ isoform expression and agonist effects in normal and malignant prostate cells," Cancer Epidemiology, Biomarkers & Prevention, vol. 13, no. 11, pp. 1710-1716, 2004. (Pubitemid 39482946)
13. E. Mueller, P. Sarraf, P. Tontonoz, et al., "Terminal differentiation of human breast cancer through PPARγ," Molecular Cell, vol. 1, no. 3, pp. 465-470, 1998. (Pubitemid 128378895)
14. G. Y. Zhang, N. Ahmed, C. Riley, et al., "Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma," British Journal of Cancer, vol. 92, no. 1, pp. 113-119, 2005. (Pubitemid 40188443)
15. S. Stadlmann, U. Gueth, E. Wight, L. A. Kunz-Schughart, A. Hartmann, and G. Singer, "Expression of peroxisome proliferator activated receptor γ and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma," Journal of Clinical Pathology, vol. 60, no. 3, pp. 307-310, 2007. (Pubitemid 46447749)
16. S. Hazra, K. A. Peebles, S. Sharma, J. T. Mao, and S. M. Dubinett, "The role of PPARγ in the cyclooxygenase pathway in lung cancer," PPAR Research, vol. 2008, Article ID 790568, 7 pages, 2008.
17. R. N. DuBois, R. Gupta, J. Brockman, B. S. Reddy, S. L. Krakow, and M. A. Lazar, "The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers," Carcinogenesis, vol. 19, no. 1, pp. 49-53, 1998. (Pubitemid 28376825)
18. C. Grommes, G. E. Landreth, and M. T. Heneka, "Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists," The Lancet Oncology, vol. 5, no. 7, pp. 419-429, 2004. (Pubitemid 38878045)
19. W. Placha, D. Gil, A. Dembinska-Kiec, and P. Laidler, "The effect of PPARγ ligands on the proliferation and apoptosis of human melanoma cells," Melanoma Research, vol. 13, no. 5, pp. 447-456, 2003. (Pubitemid 37266947)
20. C. Freudlsperger, I. Moll, U. Schumacher, and A. Thies, "Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro," Anti-Cancer Drugs, vol. 17, no. 3, pp. 325-332, 2006.
21. C. Hafner, A. Reichle, and T. Vogt, "New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARγ agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy," Current Cancer Drug Targets, vol. 5, no. 6, pp. 393-419, 2005. (Pubitemid 41176178)
22. A. Reichle, T. Vogt, B. Coras, et al., "Targeted combined antiinflammatory and angiostatic therapy in advancedmelanoma: a randomized phase II trial," Melanoma Research, vol. 17, no. 6, pp. 360-364, 2007. (Pubitemid 350084990)
23. A. Reichle, K. Bross, T. Vogt, et al., "Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma," Cancer, vol. 101, no. 10, pp. 2247-2256, 2004. (Pubitemid 39458680)
24. R. Simon, A. Nocito, T.Hübscher, et al., "Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer," Journal of the National Cancer Institute, vol. 93, no. 15, pp. 1141-1146, 2001. (Pubitemid 32780965)
25. L. Bubendorf, A. Nocito, H. Moch, and G. Sauter, "Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies," The Journal of Pathology, vol. 195, no. 1, pp. 72-79, 2001.
26. P. J. Wild, S. Meyer, F. Bataille, et al., "Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors," Archives of Dermatology, vol. 142, no. 4, pp. 471-476, 2006. (Pubitemid 43671647)
27. A. Nocito, L. Bubendorf, E. M. Tinner, et al., "Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade," The Journal of Pathology, vol. 194, no. 3, pp. 349-357, 2001. (Pubitemid 32624562)
28. D. Hanahan, G. Bergers, and E. Bergsland, "Less is, more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice," The Journal of Clinical Investigation, vol. 105, no. 8, pp. 1045-1047, 2000. (Pubitemid 30217688)
29. V. Hofmeister, D. Schrama, and J. C. Becker, "Anti-cancer therapies targeting the tumor stroma," Cancer Immunology, Immunotherapy, vol. 57, no. 1, pp. 1-17, 2008. (Pubitemid 350043655)
30. G. P. Vandoros, P. A. Konstantinopoulos, G. Sotiropoulou- Bonikou, et al., "PPAR-gamma is expressed and NF-KB pathway is activated and correlates positively with COX- 2 expression in stromal myofibroblasts surrounding colon adenocarcinomas," Journal of Cancer Research and Clinical Oncology, vol. 132, no. 2, pp. 76-84, 2006. (Pubitemid 41752048)
31. H. Inoue, T. Tanabe, and K. Umesono, "Feedback control of cyclooxygenase-2 expression through PPARγ," The Journal of Biological Chemistry, vol. 275, no. 36, pp. 28028-28032, 2000.
32. Ikawa H., Kameda H., Kamitani H., Baek S.J., Nixon J.B., Hsi L.C., Eling T.E., Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Experimental Cell Research. DOI 10.1006/excr.2001.5233. 2001, 267(1), 73-80.